Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

3D printed tissues may keep athletes in action
3D printed tissues may keep athletes in action
HOUSTON - (March 28, 2019) - Bioscientists are moving closer to 3D-printed artificial tissues to help heal bone and cartilage typically damaged in sports-related injuries to knees, ankles and ...
AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal
AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal
(Reuters) - AstraZeneca Plc will pay up to $6.
First gene therapy to treat rare blood disease nears European approval
First gene therapy to treat rare blood disease nears European approval
The first gene therapy to treat a rare blood disorder is one step closer to approval Friday following a recommendation by European officials.
FDA approves treatment for patients with a type of inflammatory arthritis
FDA approves treatment for patients with a type of inflammatory arthritis
SILVER SPRING, Md.
Number of prescription rises but cost falls again
Number of prescription rises but cost falls again
Latest data from NHS Digital shows an increase in the number of prescription items dispensed in the community, but a drop in their cost to the NHS.
New pharma Azadyne raises £1.5m for autoimmune disease treatment
New pharma Azadyne raises £1.5m for autoimmune disease treatment
Trinity College’s new spin-out organisation, Azadyne, has completed a £1.
Proteostasis Therapeutics Announces Broad New Dataset from Proprietary Combination and Add-On CFTR Modulator Studies in Cystic Fibrosis Patients
Proteostasis Therapeutics Announces Broad New Dataset from Proprietary Combination and Add-On CFTR Modulator Studies in Cystic Fibrosis Patients
BOSTON, March 25, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc.
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
BOTHELL, Wash.
Big Pharma accused of 'endless talk, no action' on antibiotic threat
Big Pharma accused of 'endless talk, no action' on antibiotic threat
LONDON (Reuters) - The pharmaceutical industry should match its words with action on researching new antibiotics to address the threat posed by drug-resistant superbugs, a former UK government...
Brain stem cells age faster in multiple sclerosis patients: study
Brain stem cells age faster in multiple sclerosis patients: study
LOS ANGELES, March 26 (Xinhua) -- Brain stem cells in the human body with the most severe form of multiple sclerosis (MS) look much older than they actually are, according to a study l...
Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis
Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis
LEXINGTON, Mass.
FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
EAST HANOVER, N.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand